Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib

Lung Cancer. 2013 Nov;82(2):365-7. doi: 10.1016/j.lungcan.2013.08.012. Epub 2013 Aug 19.

Abstract

BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations.

Keywords: BRAF; Biomarker; Dabrafenib; Lung cancer; Melanoma; Targeted therapy; Vemurafenib.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Adenocarcinoma of Lung
  • Aged
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Codon
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Indoles / chemistry
  • Indoles / therapeutic use*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Male
  • Models, Molecular
  • Molecular Conformation
  • Mutation*
  • Positron-Emission Tomography
  • Proto-Oncogene Proteins B-raf / chemistry
  • Proto-Oncogene Proteins B-raf / genetics*
  • Sulfonamides / chemistry
  • Sulfonamides / therapeutic use*
  • Tomography, X-Ray Computed
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Codon
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf